Loading…
Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites
Malaria sterile immunity has been reproducibly induced by immunization with Plasmodium radiation-attenuated sporozoites (RAS). Analyses of sera from RAS-immunized individuals allowed the identification of P. falciparum antigens, such as the circumsporozoite protein (CSP), the basis for the RTS, S an...
Saved in:
Published in: | Scientific reports 2024-02, Vol.14 (1), p.2790-2790, Article 2790 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Malaria sterile immunity has been reproducibly induced by immunization with
Plasmodium
radiation-attenuated sporozoites (RAS). Analyses of sera from RAS-immunized individuals allowed the identification of
P. falciparum
antigens, such as the circumsporozoite protein (CSP), the basis for the RTS, S and R21Matrix-M vaccines. Similar advances in
P. vivax
(
Pv
) vaccination have been elusive. We previously reported 42% (5/12) of sterile protection in malaria-unexposed, Duffy-positive (Fy +) volunteers immunized with
Pv
RAS followed by a controlled human malaria infection (CHMI). Using a custom protein microarray displaying 515
Pv
antigens, we found a significantly higher reactivity to
Pv
CSP and one hypothetical protein (PVX_089630) in volunteers protected against
P. vivax
infection. In mock-vaccinated Fy + volunteers, a strong antibody response to CHMI was also observed. Although the Fy- volunteers immunized with non-irradiated
Pv
-infected mosquitoes (live sporozoites) did not develop malaria after CHMI, they recognized a high number of antigens, indicating the temporary presence of asexual parasites in peripheral blood. Together, our findings contribute to the understanding of the antibody response to
P.
vivax
infection and allow the identification of novel parasite antigens as vaccine candidates.
Trial registration:
ClinicalTrials.gov number: NCT 01082341. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-024-53175-0 |